EFFECTS OF TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB ON PATIENT REPORTED OUTCOMES IN A PHASE 3 STUDY OF ACTIVE RHEUMATOID ARTHRITIS

被引：1
|
作者：
van Vollenhoven, R. F. [1 ]
Wallenstein, G. [2 ]
Lee, E. B. [3 ]
Fleischmann, R. [4 ]
Zwillich, S. H. [2 ]
Gruben, D. [2 ]
Koncz, T. [5 ]
Bradley, J. [2 ]
Wilkinson, B. [2 ]
Strand, V. [6 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Pfizer Inc, Groton, CT USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Metroplex Clin Res Ctr, Dallas, TX USA
[5] Pfizer Inc, New York, NY USA
[6] Stanford Univ, Palo Alto, CA 94304 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2116
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [41] ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
    Strand, V.
    van der Heijde, D.
    Zerbini, C. A. F.
    Connell, C. A.
    Gruben, D.
    Riese, R.
    Wallenstein, G.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S996 - S997
  • [42] Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.
    Strand, V.
    Kremer, J. M.
    Li, Z. G.
    Hall, S.
    Fleischmann, Roy M.
    Genovese, M. C.
    Martin-Mola, E.
    Isaacs, J.
    Gruben, D.
    Wallenstein, G.
    Krishnaswami, S.
    Zwillich, S. H.
    Koncz, T.
    Riese, R.
    Bradley, J. D.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1032 - S1032
  • [43] ORAL START: EFFECTS OF THE ORAL JAK INHIBITOR TOFACITINIB MONOTHERAPY VERSUS METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN THE PHASE 3 ORAL START TRIAL OF ACTIVE RHEUMATOID ARTHRITIS
    Strand, V.
    Fleischmann, R.
    Alten, R. E.
    Koncz, T.
    Zwillich, S. H.
    Bradley, J. D.
    Gruben, D.
    Wilkinson, B.
    Krishaswami, S.
    Wallenstein, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 252 - 253
  • [44] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN A RHEUMATOID ARTHRITIS OPEN-LABEL EXTENSION STUDY FOLLOWING ADALIMUMAB THERAPY IN A PHASE 3 RANDOMISED CLINICAL TRIAL
    Genovese, M.
    van Vollenhoven, R.
    Wilkinson, B.
    Wang, L.
    Zwillich, S.
    Gruben, D.
    Benda, B.
    Jones, T.
    Bradley, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 65
  • [45] Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
    Genovese, M. C.
    van Vollenhoven, R. F.
    Wilkinson, B.
    Wang, L.
    Zwillich, S. H.
    Gruben, D.
    Benda, B.
    Jones, T. V.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S190 - S191
  • [46] Open label study of the pharmacokinetics of a JAK3 antagonist (CP-690,550) and single doses of oral methotrexate in rheumatoid arthritis subjects.
    Chow, V.
    Wilkinson, B.
    LaBadie, R.
    Ni, G.
    Zwillich, S. H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S36 - S36
  • [47] Effects Of VX-509, An Investigational Oral Selective Janus Kinase 3 (JAK3) Inhibitor, On Patient-Reported Outcomes In a Phase 2A Study Of Patients With Active Rheumatoid Arthritis
    Strand, Vibeke
    Suthoff, Ellison
    Fleischmann, Roy M.
    Vera-Llonch, Montserrat
    Jiang, John
    Zhang, Yanqiong
    Kinnman, Nils
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S1004 - S1005
  • [48] The itch severity item: Mediation modeling and measurement characteristics from a phase IIb trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis
    Mamolo, Carla
    Bushmakin, Andrew
    Harness, Jane
    Cappelleri, Joseph
    Stewart, Michelle
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB152 - AB152
  • [49] Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
    van der Heijde, Desiree
    Tanaka, Yoshiya
    Fleischmann, Roy
    Keystone, Edward
    Kremer, Joel
    Zerbini, Cristiano
    Cardiel, Mario H.
    Cohen, Stanley
    Nash, Peter
    Song, Yeong-Wook
    Tegzova, Dana
    Wyman, Bradley T.
    Gruben, David
    Benda, Birgitta
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Bradley, John D.
    Connell, Carol A.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (03): : 559 - 570
  • [50] CP-690,550, an oral JAK inhibitor, is a well-tolerated and effective long-term treatment for patients with moderate to severe rheumatoid arthritis
    Silverfield, J.
    Connell, C.
    Bloom, B.
    Groben, D.
    Kanik, K.
    Poiley, J. E.
    Polak, P.
    Burson, J. Sanchez
    Tate, G.
    Wallenstein, G.
    Wilkinson, B.
    Zwillich, S. H.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S432 - S432
12345